Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.74 |
| ▸ | ACE | P12821 | 3/20 | 0.74 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.42 |
| ▸ | FNTA | P49354 | 3/20 | 0.41 |
| ▸ | FNTB | P49356 | 3/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8249107 | 1.00 | ACE2 (0.74) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL8249920 | 0.90 | ACE2 (0.76) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL1690702 | 0.90 | ACE2 (0.76) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL8249359 | 0.90 | ACE2 (0.82) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL1658960 | 0.90 | ACE2 (0.82) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL8248569 | 0.90 | ACE2 (0.78) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL5870208 | 0.90 | ACE2 (0.78) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL5870244 | 0.89 | ACE2 (0.74) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL5869930 | 0.89 | ACE2 (0.74) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL1690920 | 0.89 | ACE2 (0.77) | ACE2ACECYP11B1CYP11B2FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | claimed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | claimed |
| US-6632830-B1 | Blood pressure related disease or disorder, cell proliferation disorder, kidney disorder, kinetensin associated disorder, inflammation associated disorder, or an allergic disorder | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | claimed |
| JP-2002543120-A | — | — | 2002-12-17 | — | — | JP | claimed |
| CN-1377259-A | ACE-2 inhibiting compounds and methods of use thereof | MILLENNIUM PHARM INC (US) | 2002-10-30 | — | — | CN | claimed |
| WO-2000066104-A9 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2002-08-29 | — | — | WO | claimed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | claimed |
| EP-1183019-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2002-03-06 | — | — | EP | claimed |
| WO-2000066104-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-11-09 | — | — | WO | claimed |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| US-11337909-B2 | Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2022-05-24 | — | — | US | disclosed |
| US-20200360258-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2020-11-19 | — | — | US | disclosed |
| EP-3717077-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2020-10-07 | — | — | EP | disclosed |
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6632830-B1 | Blood pressure related disease or disorder, cell proliferation disorder, kidney disorder, kinetensin associated disorder, inflammation associated disorder, or an allergic disorder | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | disclosed |
| CN-1377259-A | ACE-2 inhibiting compounds and methods of use thereof | MILLENNIUM PHARM INC (US) | 2002-10-30 | — | — | CN | disclosed |
| WO-2000066104-A9 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | ACE2 2/4885ACE 1/4885CYP11B1 256/4885 |
| US-20200360258-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | ACE, ACE2, TYR | ACE2 2/4885ACE 1/4885CYP11B1 1239/4885 |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | ACE2 1/4885ACE 2/4885CYP11B1 3069/4885 |
| US-11337909-B2 | Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation | ACE, ACE2, TYR | ACE2 2/4885ACE 1/4885CYP11B1 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.